BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION
PROGRAM.
(a) In General.--
Introduced:
Feb 21, 2025
Policy Area:
Health
Congress.gov:
Bill Statistics
4
Actions
64
Cosponsors
1
Summaries
4
Subjects
1
Text Versions
Yes
Full Text
AI Summary
AI Summary
No AI Summary Available
Click the button above to generate an AI-powered summary of this bill using Claude.
The summary will analyze the bill's key provisions, impact, and implementation details.
Error generating summary
Latest Action
Feb 21, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summaries (1)
Introduced in House
- Feb 21, 2025
00
<p>This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.</p><p>The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. </p><p>The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.</p><p>The bill's changes apply retroactively.</p>
Actions (4)
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Type: IntroReferral
| Source: House floor actions
| Code: H11100
Feb 21, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Type: IntroReferral
| Source: House floor actions
| Code: H11100
Feb 21, 2025
Introduced in House
Type: IntroReferral
| Source: Library of Congress
| Code: Intro-H
Feb 21, 2025
Introduced in House
Type: IntroReferral
| Source: Library of Congress
| Code: 1000
Feb 21, 2025
Subjects (4)
Health
(Policy Area)
Health care costs and insurance
Medicare
Prescription drugs
Cosponsors (20 of 64)
(R-WI)
Apr 8, 2025
Apr 8, 2025
(R-KY)
Apr 1, 2025
Apr 1, 2025
(R-PA)
Apr 1, 2025
Apr 1, 2025
(R-MD)
Apr 1, 2025
Apr 1, 2025
(R-NC)
Apr 1, 2025
Apr 1, 2025
(R-TX)
Mar 26, 2025
Mar 26, 2025
(R-TX)
Mar 25, 2025
Mar 25, 2025
(R-IN)
Mar 24, 2025
Mar 24, 2025
(R-FL)
Mar 24, 2025
Mar 24, 2025
(R-TX)
Mar 24, 2025
Mar 24, 2025
(R-NY)
Mar 24, 2025
Mar 24, 2025
(R-NC)
Mar 24, 2025
Mar 24, 2025
(R-IA)
Mar 24, 2025
Mar 24, 2025
(R-WV)
Mar 24, 2025
Mar 24, 2025
(R-NY)
Mar 24, 2025
Mar 24, 2025
(R-NJ)
Mar 24, 2025
Mar 24, 2025
(R-FL)
Mar 24, 2025
Mar 24, 2025
(R-TX)
Mar 24, 2025
Mar 24, 2025
(R-NC)
Feb 21, 2025
Feb 21, 2025
(D-NC)
Feb 21, 2025
Feb 21, 2025
Showing latest 20 cosponsors
Full Bill Text
Length: 1,769 characters
Version: Introduced in House
Version Date: Feb 21, 2025
Last Updated: Nov 14, 2025 6:09 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1492 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. R. 1492
To amend title XI of the Social Security Act to equalize the
negotiation period between small-molecule and biologic candidates under
the Drug Price Negotiation Program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 21, 2025
Mr. Murphy (for himself, Mr. Davis of North Carolina, and Mr. Hudson)
introduced the following bill; which was referred to the Committee on
Energy and Commerce, and in addition to the Committee on Ways and
Means, for a period to be subsequently determined by the Speaker, in
each case for consideration of such provisions as fall within the
jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend title XI of the Social Security Act to equalize the
negotiation period between small-molecule and biologic candidates under
the Drug Price Negotiation Program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
[From the U.S. Government Publishing Office]
[H.R. 1492 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. R. 1492
To amend title XI of the Social Security Act to equalize the
negotiation period between small-molecule and biologic candidates under
the Drug Price Negotiation Program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 21, 2025
Mr. Murphy (for himself, Mr. Davis of North Carolina, and Mr. Hudson)
introduced the following bill; which was referred to the Committee on
Energy and Commerce, and in addition to the Committee on Ways and
Means, for a period to be subsequently determined by the Speaker, in
each case for consideration of such provisions as fall within the
jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend title XI of the Social Security Act to equalize the
negotiation period between small-molecule and biologic candidates under
the Drug Price Negotiation Program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.
Section 1192
(e)
(1)
(A)
(ii) of the Social Security
Act (42 U.
(e)
(1)
(A)
(ii) of the Social Security
Act (42 U.S.C. 1320f-1
(e)
(1)
(A)
(ii) ) is amended by striking ``7 years''
and inserting ``11 years''.
(b) Effective Date.--The amendment made by subsection
(a) shall
take effect as if included in the enactment of Public Law 117-169.
<all>